Collaborations envisagées

Dans un autre contexte, nous souhaiterions développer une collaboration avec une équipe lilloise qui applique des techniques informatiques éprouvées aux données biomédicales. En particulier, les chercheurs ont développé une méthodologie de recherche dans le domaine de l’informatique médicale et des biostatistiques, notamment dans le but d’améliorer les

techniques de détection des évènements indésirables médicamenteux à partir de sources de données hospitalières (Chazard 2011, 2011, 2012).

Une collaboration, mise en perspective des résultats apportés par nos travaux de thèse, pourrait permettre de développer une méthodologie similaire, mais spécifiquement dédiée aux substances psychoactives et aux problématiques que cela engendre habituellement. Cette méthodologie devrait donc être extrapolable au réseau français des CEIP-Addictovigilance afin d’améliorer l’identification des complications de l’usage de ces substances, mais serait également utile à l’équipe d’accueil dans le cadre d’études sur des molécules à potentiel d’abus et de dépendance.

Références bibliographiques

Ahmed SH, Lenoir M, Guillem K. Neurobiology of addiction versus drug use driven by lack of choice. Curr. Opin. Neurobiol. 2013; 23: 581‑7.

Ameri A. The effects of cannabinoids on the brain. Prog. Neurobiol. 1999; 58: 315‑348. APA. DSM-IV-TR : Manuel diagnostique et statistique des troubles mentaux, texte révisé.

American psychiatric association (APA). Issy-les-Moulineaux: Masson Editeur; 2004.

Appelboam A, Oades PJ. Coma due to cannabis toxicity in an infant. Eur. J. Emerg. Med. Off. J. Eur. Soc. Emerg. Med. juin 2006; 13: 177‑179.

Aronow WS, Cassidy J. Effect of smoking marihuana and of a high-nicotine cigarette on angina pectoris. Clin. Pharmacol. Ther. 1975; 17: 549‑554.

Arora S, Goyal H, Aggarwal P, Kukar A. ST-segment elevation myocardial infarction in a 37- year-old man with normal coronaries--it is not always cocaine! Am. J. Emerg. Med. nov 2012; 30: 2091.e3‑5.

Aryana A, Williams MA. Marijuana as a trigger of cardiovascular events: speculation or scientific certainty? Int. J. Cardiol. 31 mai 2007; 118: 141‑144.

Asbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ. 2012; 344: e536‑e536.

Asensio S, Romero MJ, Palau C, Sanchez A, Senabre I, Morales JL, Carcelen R, Romero FJ. Altered neural response of the appetitive emotional system in cocaine addiction: an fMRI Study. Addict. Biol. 2010; 15: 504‑516.

Ashton CH. Pharmacology and effects of cannabis: a brief review. Br. J. Psychiatry J. Ment. Sci. 2001; 178: 101‑106.

Bachs L, Mørland H. Acute cardiovascular fatalities following cannabis use. Forensic Sci. Int. 2001; 124: 200‑203.

Barber PA, Pridmore HM, Krishnamurthy V, Roberts S, Spriggs DA, Carter KN, Anderson NE. Cannabis, Ischemic Stroke, and Transient Ischemic Attack: A Case-Control Study. Stroke J. Cereb. Circ. 2013; 44: 2327‑9.

Bátkai S, Pacher P. Endocannabinoids and cardiac contractile function: pathophysiological implications. Pharmacol. Res. Off. J. Ital. Pharmacol. Soc. 2009; 60: 99‑106.

Baumevieille M, Miremont G, Haramburu F, Maurain C, Bégaud B. The French system of evaluation of dependence: establishment in a legal system [French]. Therapie. 2001; 56: 15‑22.

Baumevieille M, Daveluy A, Maurain C, Bégaud B, Haramburu F. Medicines submitted to narcotics regulations in France, 1992-2007. Fundam. Clin. Pharmacol. 2009; 23: 345‑349. Beck F, Legleye S, Spilka S. Cannabis, cocaïne, ecstasy: entre expérimentation et usage

régulier. Baromètre Santé 2005 [Internet]. Institut national de prévention et d’éducation pour la santé (INPES). Saint-Denis; 2007. p. 169‑221. Disponible sur: http://www.inpes.sante.fr/CFESBases/catalogue/pdf/1109.pdf

Beck F, Legleye S, Obradovic I, Mutatayi C, Cohen B, Karila L. [Drug use among youths]. Médecine Sci. MS. 2008; 24: 758‑767.

Beck F, Guignard R, Tovar M, Spilka S. Les niveaux d’usage des drogues en France en 2010 - Exploitation des données du Baromètre santé. Tendances. OFDT. 2011; 76:6p.

Begaud B, Martin K, Haramburu F, Moore N. Rates of spontaneous reporting of adverse drug reactions in France. JAMA J. Am. Med. Assoc. 2002; 288: 1588.

Benowitz NL, Jones RT. Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion. Clin. Pharmacol. Ther. 1975; 18: 287‑297.

Benson MK, Bentley AM. Lung disease induced by drug addiction. Thorax. 1995; 50: 1125‑1127.

Bishop YMM, Fienberg SE, Holland PW. Discrete multivariate analysis : Theory and practice. New York, NY, USA: Springer Science + Business Media, LLC; 2007.

Boeuf O, Lapeyre-Mestre M. Survey of forged prescriptions to investigate risk of psychoactive medications abuse in France: results of OSIAP survey. Drug Saf. Int. J. Med. Toxicol. Drug Exp. 2007; 30: 265‑276.

Butler SF, Budman SH, Licari A, Cassidy TA, Lioy K, Dickinson J, Brownstein JS, Benneyan JC, Green TC, Katz N. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiol. Drug Saf. 2008; 17: 1142‑1154. Butler SF, Black RA, Cassidy TA, Dailey TM, Budman SH. Abuse risks and routes of

administration of different prescription opioid compounds and formulations. Harm. Reduct. J. 2011; 8: 29.

Cai R, Crane E, Poneleit K, Paulozzi L. Emergency department visits involving nonmedical use of selected prescription drugs in the United States, 2004-2008. J. Pain Palliat. Care Pharmacother. 2010; 24: 293‑297.

Cappelli F, Lazzeri C, Gensini GF, Valente S. Cannabis: a trigger for acute myocardial infarction? A case report. J. Cardiovasc. Med. Hagerstown Md. 2008; 9: 725‑728.

Carstairs SD, Fujinaka MK, Keeney GE, Ly BT. Prolonged coma in a child due to hashish ingestion with quantitation of THC metabolites in urine. J. Emerg. Med. 2011; 41: e69‑71. Chao A, Tsay PK, Lin SH, Shau WY, Chao DY. The applications of capture-recapture

Chazard E, Băceanu A, Ferret L, Ficheur G. The ADE scorecards: a tool for adverse drug event detection in electronic health records. Stud. Health Technol. Inform. 2011; 166: 169‑179.

Chazard E, Ficheur G, Bernonville S, Luyckx M, Beuscart R. Data mining to generate adverse drug events detection rules. IEEE Trans. Inf. Technol. Biomed. Publ. IEEE Eng. Med. Biol. Soc. 2011; 15: 823‑830.

Chazard E, Bernonville S, Ficheur G, Beuscart R. A statistics-based approach of contextualization for adverse drug events detection and prevention. Stud. Health Technol. Inform. 2012; 180: 766‑770.

Cicero TJ, Dart RC, Inciardi JA, Woody GE, Schnoll S, Muñoz A. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS). Pain Med. Malden Mass. 2007; 8: 157‑170.

Cole C, Jones L, McVeigh J, Kicman A, Syed Q, Bellis M. Adulterants in illicit drugs: a review of empirical evidence. Drug Test. Anal. 2011; 3: 89‑96.

Cormack RM. Interval Estimation for Mark-Recapture Studies of Closed Populations. Biometrics. 1992; 48: 567‑576.

Corrigan D. The pharmacology of cannabis: issues for understanding its use. Cannabis Read. Glob. Issues Local Exp. Monogr. Ser. 8 Vol. 1. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction; 2008. p. 27‑37.

Costes J-M. Cannabis, données essentielles. Saint-Denis, France: OFDT; 2007. p. 232. Cota D, Steiner M-A, Marsicano G, Cervino C, Herman JP, Grübler Y, Stalla J, Pasquali R,

Lutz B, Stalla GK, Pagotto U. Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function. Endocrinology. 2007; 148: 1574‑1581.

Cottencin O, Karila L, Lambert M, Arveiller C, Benyamina A, Boissonas A, Goudemand M, Reynaud M. Cannabis arteritis: review of the literature. J. Addict. Med. 2010; 4: 191‑196. Cox S, Shipley M. Counting the uncatchable? An epidemiological method for counting drug

misusers. Soc. Psychiatry Psychiatr. Epidemiol. 1997; 32: 19‑23.

Crane NA, Schuster RM, Fusar-Poli P, Gonzalez R. Effects of Cannabis on Neurocognitive Functioning: Recent Advances, Neurodevelopmental Influences, and Sex Differences. Neuropsychol. Rev. 2012; 23: 117‑37.

CSP. Arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants. Version consolidée au 4 novembre 2012 [Internet]. 1990. Disponible sur: http://www.legifrance.gouv.fr/affichTexte.do;jsessionid=D469F417A98D389B1A956FA921 49A2AC.tpdjo05v_3?cidTexte=JORFTEXT000000533085&dateTexte=20130521

CSP. Article R.5132-114 du 8 août 2004 [Internet]. 2004. Disponible sur: http://www.legifrance.gouv.fr/affichCodeArticle.do;jsessionid=619DB47C93353C5E7CC664 DB9F25526F.tpdjo02v_1?idArticle=LEGIARTI000006915744&cidTexte=LEGITEXT00000 6072665&dateTexte=20120514

CSP. Article L.3421-1 du 5 mars 2007 relatif à la pénalisation de l’usage illicite de

stupéfiants [Internet]. 2007. Disponible sur:

http://www.legifrance.gouv.fr/affichCodeArticle.do?idArticle=LEGIARTI000006688173&ci dTexte=LEGITEXT000006072665&dateTexte=20130516

CSP. Articles R.5132-97 et 98 du 5 février 2007 [Internet]. 2007. Disponible sur: http://www.legifrance.gouv.fr/affichCode.do?idArticle=LEGIARTI000006915722&idSection TA=LEGISCTA000006196619&cidTexte=LEGITEXT000006072665&dateTexte=20111123 CSP. Article L.6113-7 Modifié par Ordonnance n°2010-177 du 23 février 2010 - art. 4

[Internet]. 2010. Disponible sur:

http://www.legifrance.gouv.fr/affichCodeArticle.do?cidTexte=LEGITEXT000006072665&id Article=LEGIARTI000006690711

CSP. Article L.6113-8 Modifié par Ordonnance n°2010-177 du 23 février 2010 - art. 9 (V)

[Internet]. 2010. Disponible sur:

http://www.legifrance.gouv.fr/affichCodeArticle.do?cidTexte=LEGITEXT000006072665&id Article=LEGIARTI000006690711

CSP. Arrêté du 30 juin 2011 relatif au recueil et au traitement des données d’activité médicale des établissements de santé publics ou privés ayant une activité en soins de suite et de réadaptation et à la transmission d’informations issues de ce traitement, dans les conditions définies aux articles L. 6113-7 et L. 6113-8 du code de la santé publique

[Internet]. 2011. Disponible sur:

http://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000024290191&dateTex te=&categorieLien=id

CSP. Article R.5121-152 Modifié par Décret n°2012-1244 du 8 novembre 2012 - art. 5

[Internet]. 2012. Disponible sur:

http://www.legifrance.gouv.fr/affichCode.do?idArticle=LEGIARTI000026596752&idSection TA=LEGISCTA000006196559&cidTexte=LEGITEXT000006072665&dateTexte=20130829 Dean C. Endocannabinoid modulation of sympathetic and cardiovascular responses to acute stress in the periaqueductal gray of the rat. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2011; 300: R771‑779.

Delamare J, Delamare F, Gélis-Malville E, Delamare L, Péquignot H. Dictionnaire illustré des termes de médecine Garnier-Delamare. 31ème édition. Maloine; 2012.

Demuth DG, Molleman A. Cannabinoid signalling. Life Sci. 2006; 78: 549‑563.

DiBlasio AM, Vignali M, Gentilini D. The endocannabinoid pathway and the female reproductive organs. J. Mol. Endocrinol. 2013; 50: R1‑9.

Disdier P, Granel B, Serratrice J, Constans J, Michon-Pasturel U, Hachulla E, Conri C, Devulder B, Swiader L, Piquet P, Branchereau A, Jouglard J, Moulin G, Weiller PJ. Cannabis arteritis revisited--ten new case reports. Angiology. 2001; 52: 1‑5.

Djezzar S, Questel F, Burin E, Dally S. Chemical submission: results of 4-year French inquiry. Int. J. Legal Med. 2009; 123: 213‑219.

Duchene C, Olindo S, Chausson N, Jeannin S, Cohen-Tenoudji P, Smadja D. Cannabis- induced cerebral and myocardial infarction in a young woman [French]. Rev. Neurol. (Paris). 2010; 166: 438‑442.

Dunn J, Ferri CP. Epidemiological methods for research with drug misusers: review of methods for studying prevalence and morbidity. Rev. Saúde Pública. 1999; 33: 206‑215. Effertz T, Mann K. The burden and cost of disorders of the brain in Europe with the inclusion

of harmful alcohol use and nicotine addiction. Eur. Neuropsychopharmacol. 2013; 23: 742‑8. Finsterer J, Christian P, Wolfgang K. Occipital stroke shortly after cannabis consumption.

Clin. Neurol. Neurosurg. 2004; 106: 305‑308.

Fratta W, Fattore L. Molecular mechanisms of cannabinoid addiction. Curr. Opin. Neurobiol. 2013; 23: 487‑492.

Frauger E, Vigneau C, Orléans V, Thirion X, Jolliet P, Micallef J, Réseau des CEIP. Consumption of cannabis among subjects with history of abuse/dependence or under an opiate maintenance therapy: OPPIDUM data in 2006 and main trends since 2004 [French]. Therapie. 2008; 63: 119‑127.

Frauger E, Pauly V, Natali F, Pradel V, Reggio P, Coudert H, Thirion X, Micallef J. Patterns of methylphenidate use and assessment of its abuse and diversion in two French administrative areas using a proxy of deviant behaviour determined from a reimbursement database: main trends from 2005 to 2008. CNS Drugs. 2011; 25: 415‑424.

Frauger E, Pauly V, Pradel V, Rouby F, Arditti J, Thirion X, Lapeyre Mestre M, Micallef J. Evidence of clonazepam abuse liability: results of the tools developed by the French Centers for Evaluation and Information on Pharmacodependence (CEIP) network. Fundam. Clin. Pharmacol. 2011; 25: 633‑641.

Frauger E, Moracchini C, Le Boisselier R, Braunstein D, Thirion X, Micallef J. OPPIDUM surveillance program: 20 years of information on drug abuse in France. Fundam. Clin. Pharmacol. 2013; [Epub ahead of print].

Gallay A, Nardone A, Vaillant V, Desenclos JC. The capture-recapture applied to epidemiology: principles, limits and application [French]. Rev Epidemiol Sante Publique. 2002; 50: 219‑232.

García-Gil MDM, Hermosilla E, Prieto-Alhambra D, Fina F, Rosell M, Ramos R, Rodriguez J, Williams T, Van Staa T, Bolíbar B. Construction and validation of a scoring system for the selection of high-quality data in a Spanish population primary care database (SIDIAP). Inform. Prim. Care. 2011; 19: 135‑145.

Garland EL, Howard MO. Volatile substance misuse : clinical considerations, neuropsychopharmacology and potential role of pharmacotherapy in management. CNS Drugs. 2012; 26: 927‑935.

Gorelick DA, Heishman SJ. Methods for clinical research involving cannabis administration. Methods Mol. Med. 2006; 123: 235‑253.

Gorelick DA, Goodwin RS, Schwilke E, Schwope DM, Darwin WD, Kelly DL, McMahon RP, Liu F, Ortemann-Renon C, Bonnet D, Huestis MA. Tolerance to effects of high-dose oral δ9-tetrahydrocannabinol and plasma cannabinoid concentrations in male daily cannabis smokers. J. Anal. Toxicol. 2013; 37: 11‑16.

Gorzalka BB, Hill MN, Chang SCH. Male-female differences in the effects of cannabinoids on sexual behavior and gonadal hormone function. Horm. Behav. 2010; 58: 91‑99.

Graham JD. Cannabis and the cardiovascular system. Br. Med. J. 1978; 1: 857.

Grassin F, André M, Rallec B, Combes E, Vinsonneau U, Paleiron N. Fatal alveolar haemorrhage following a « bang » of cannabis [French]. Rev. Mal. Respir. 2011; 28: 919‑923.

Hamm CW, Bassand J-P, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D, ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 2011; 32: 2999‑3054.

Hibell B, Guttormsson U, Ahlström S, Balakireva O, Bjarnason T, Kokkevi A, Kraus L. The 2011 ESPAD Report - Substance Use Among Students in 36 European Countries. Stockholm, Sweden: The Swedish Council for Information on Alcohol and Other Drugs (CAN); 2012

[cité 1 sept 2013]. p. 394. Disponible sur:

http://www.espad.org/Uploads/ESPAD_reports/2011/The_2011_ESPAD_Report_FULL_201 2_10_29.pdf

Hobbs FDR, Jukema JW, Da Silva PM, McCormack T, Catapano AL. Barriers to cardiovascular disease risk scoring and primary prevention in Europe. QJM Mon. J. Assoc. Physicians. 2010; 103: 727‑739.

Hook EB, Regal RR. Recommendations for presentation and evaluation of capture-recapture estimates in epidemiology. J. Clin. Epidemiol. 1999; 52: 917‑926; discussion 929‑933. Hook EB, Regal RR. Validity of Methods for Model Selection, Weighting for Model

Uncertainty, and Small Sample Adjustment in Capture-Recapture Estimation. Am. J. Epidemiol. 1997; 145: 1138 ‑1144.

Hook EB, Regal RR. On the need for a 16th and 17th recommendation for capture–recapture analysis. J. Clin. Epidemiol. 2000; 53: 1275‑1276.

Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 2002; 54: 161‑202.

Hunault CC, Mensinga TT, de Vries I, Kelholt-Dijkman HH, Hoek J, Kruidenier M, Leenders MEC, Meulenbelt J. Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC. Psychopharmacology (Berl.). 2008; 201: 171‑181.

INCB. List of Psychotropic Substances under International Control: Green list, 24th edition [Internet]. International Narcotics Control Board (INCB); 2010 [cité 1 sept 2013]. Disponible sur:

http://www.incb.org/documents/Psychotropics/green_lists/Green_list_ENG_2010_53991_wit h_logo.pdf

INSERM (dir.). Cannabis − Quels effets sur le comportement et la santé ? Rapport. Paris: Les éditions INSERM; 2001 [cité 1 sept 2013]. p. 429. Disponible sur: http://hdl.handle.net/10608/171

Járai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, Zimmer AM, Bonner TI, Buckley NE, Mezey E, Razdan RK, Zimmer A, Kunos G. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. U. S. A. 1999; 96: 14136‑14141.

Jones RT. Cardiovascular system effects of marijuana. J. Clin. Pharmacol. 2002; 42: 58S‑63S.

Jouanjus E, Leymarie F, Tubery M, Lapeyre-Mestre M. Cannabis-related hospitalizations: unexpected serious events identified through hospital databases. Br. J. Clin. Pharmacol. 2011; 71: 758‑765.

Jouanjus E, Pourcel L, Saivin S, Molinier L, Lapeyre-Mestre M. Use of multiple sources and capture–recapture method to estimate the frequency of hospitalizations related to drug abuse. Pharmacoepidemiol. Drug Saf. 2012; 21: 733‑41.

Joyeux M, Arnaud C, Godin-Ribuot D, Demenge P, Lamontagne D, Ribuot C. Endocannabinoids are implicated in the infarct size-reducing effect conferred by heat stress preconditioning in isolated rat hearts. Cardiovasc. Res. 2002; 55: 619‑625.

Karabulut A, Cakmak M. ST segment elevation myocardial infarction due to slow coronary flow occurring after cannabis consumption. Kardiol. Pol. 2010; 68: 1266‑1268.

Kissela BM, Khoury JC, Alwell K, Moomaw CJ, Woo D, Adeoye O, Flaherty ML, Khatri P, Ferioli S, De Los Rios La Rosa F, Broderick JP, Kleindorfer DO. Age at stroke: temporal trends in stroke incidence in a large, biracial population. Neurology. 2012; 79: 1781‑1787. Koethe D, Gerth CW, Neatby MA, Haensel A, Thies M, Schneider U, Emrich HM,

Klosterkötter J, Schultze-Lutter F, Leweke FM. Disturbances of visual information processing in early states of psychosis and experimental delta-9-tetrahydrocannabinol altered states of consciousness. Schizophr. Res. 2006; 88: 142‑150.

Kreek MJ, Levran O, Reed B, Schlussman SD, Zhou Y, Butelman ER. Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics. J. Clin. Invest. 2012;

122: 3387‑3393.

Kuepper R, Morrison PD, van Os J, Murray RM, Kenis G, Henquet C. Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines. Schizophr. Res. 2010; 121: 107‑117.

Kunos G, Osei-Hyiaman D, Liu J, Godlewski G, Bátkai S. Endocannabinoids and the control of energy homeostasis. J. Biol. Chem. 2008; 283: 33021‑33025.

Kwolek G, Zakrzeska A, Schlicker E, Göthert M, Godlewski G, Malinowska B. Central and peripheral components of the pressor effect of anandamide in urethane-anaesthetized rats. Br. J. Pharmacol. 2005; 145: 567‑575.

Larrieu C. Les conséquences graves de l’abus d’opiacés dans la région toulousaine. Mémoire de Stage de M1 Biologie Santé. Toulouse: EA 3696: Unité de Pharmacoépidémiologie, Laboratoire de Pharmacologie Clinique, UPS, Université de Toulouse III; 2010 p. 16.

Larson A, Bammer G. Why? Who? How? Estimating numbers of illicit drug users: lessons from a case study from the Australian Capital Territory. Aust. N. Z. J. Public Health. 1996;

20: 493‑499.

Leblanc A, Tirel-Badets A, Paleiron N, Castellant P, Cornily J-C, Andre M, Grassin F, Feuvrier Y, Blanchard C, Zagnoli F, Quiniou G, Vinsonneau U. [Cannabis and myocardial infarction without angiographic stenosis in young patient: guilty or not guilty? A case report]. Ann. Cardiol. Angéiologie. 2011; 60: 154‑158.

Leweke FM, Schneider U, Radwan M, Schmidt E, Emrich HM. Different effects of nabilone and cannabidiol on binocular depth inversion in Man. Pharmacol. Biochem. Behav. 2000;

66: 175‑181.

Loftis JM, Huckans M. Substance use disorders: Psychoneuroimmunological mechanisms and new targets for therapy. Pharmacol. Ther. 2013; 139: 289‑300.

Lott IT, McGregor M, Engelman L, Touchette P, Tournay A, Sandman C, Fernandez G, Plon L, Walsh D. Longitudinal prescribing patterns for psychoactive medications in community- based individuals with developmental disabilities: utilization of pharmacy records. J. Intellect. Disabil. Res. JIDR. 2004; 48: 563‑571.

Lugardon S, Desboeuf K, Fernet P, Montastruc J-L, Lapeyre-Mestre M. Using a capture- recapture method to assess the frequency of adverse drug reactions in a French university hospital. Br. J. Clin. Pharmacol. 2006; 62: 225‑231.

Maldonado R. Study of cannabinoid dependence in animals. Pharmacol. Ther. 2002; 95: 153‑164.

Maldonado R. Propriétés addictives des cannabinoïdes et rôle du système endocannabinoïde dans l’addiction, XIIèmes Rencontres du CEIP de Toulouse. Présentation orale. Toulouse; 2008.

Maldonado R, Berrendero F, Ozaita A, Robledo P. Neurochemical basis of cannabis addiction. Neuroscience. 2011; 181: 1‑17.

Mallaret M, Dal’Bo-Rohrer D, Demattéis M. Adverse effects of marijuana [French]. Rev. Prat. 2005; 55: 41‑49.

Mateo I, Pinedo A, Gomez-Beldarrain M, Basterretxea JM, Garcia-Monco JC. Recurrent stroke associated with cannabis use. J. Neurol. Neurosurg. Psychiatry. 2005; 76: 435‑437. Mathew RJ, Wilson WH, Davis R. Postural syncope after marijuana: a transcranial Doppler

study of the hemodynamics. Pharmacol. Biochem. Behav. 2003; 75: 309‑318.

Matsunaga T, Kishi N, Higuchi S, Watanabe K, Ohshima T, Yamamoto I. CYP3A4 is a major isoform responsible for oxidation of 7-hydroxy-Delta(8)-tetrahydrocannabinol to 7-oxo- delta(8)-tetrahydrocannabinol in human liver microsomes. Drug Metab. Dispos. Biol. Fate Chem. 2000; 28: 1291‑1296.

McCann UD, Edwards RR, Smith MT, Kelley K, Wilson M, Sgambati F, Ricaurte G. Altered pain responses in abstinent (±)3,4-methylenedioxymethamphetamine (MDMA, « ecstasy ») users. Psychopharmacology (Berl.). 2011; 217: 475‑484.

McMillan GP, Bedrick E, C’deBaca J. A Bayesian model for estimating the effects of drug use when drug use may be under-reported. Addict. Abingdon Engl. 2009; 104: 1820‑1826. Meuleners LB, Duke J, Lee AH, Palamara P, Hildebrand J, Ng JQ. Psychoactive medications

and crash involvement requiring hospitalization for older drivers: a population-based study. J. Am. Geriatr. Soc. 2011; 59: 1575‑1580.

Mewton L, Teesson M, Slade T, Grove R. The epidemiology of DSM-IV alcohol use disorders amongst young adults in the Australian population. Alcohol Alcohol. Oxf. Oxfs. 2011; 46: 185‑191.

Michel-Monigadon D, Steffens S, Molica F, Mach F, Montecucco F. Update on the endocannabinoid-mediated regulation of gelatinase release in arterial wall physiology and atherosclerotic pathophysiology. Expert Rev. Cardiovasc. Ther. 2012; 10: 1481‑1486. Milroy CM, Parai JL. The histopathology of drugs of abuse. Histopathology. 2011; 59:

579‑593.

Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering myocardial infarction by marijuana. Circulation. 2001; 103: 2805‑2809.

Molly C, Mory O, Basset T, Patural H. Acute cannabis poisoning in a 10-month-old infant [French]. Arch Pediatr. 2012; 19: 729‑732.

Montastruc J-L. Lexique de Pharmacologie Médicale [Internet]. Toulouse; 2011 [cité 1 sept 2013]. Disponible sur: http://www.medecine.ups-tlse.fr/pcem2/pharmacie/2011- 2012_Lexique_Pharmacologie.pdf

Montastruc J-L, Lugardon S, Desboeuf K, Fernet P, Lapeyre-Mestre M. Use of the capture- recapture method to assess the frequency of « serious » adverse drug reactions: experience of Toulouse University Hospital [French]. Bull Acad Natl Med. 2008; 192: 421‑430; discussion 430‑431.

Moracchini C, Orleans V, Miloudi S, Frauger E, Micallef J, Thirion X. General Practitioners’ Contribution to Dependence Assessment: the OPEMA Programme [French]. Therapie. 2012;

67: 397‑404.

Nair P, Robertson A, Macwalter R. An unusual cause of syncope. BMJ Case Reports. 2009; 2009.

Nations Unies. Convention de 1971 sur les substances psychotropes [Internet]. Vienna; 1971

[cité 1 sept 2013]. Disponible sur:

http://www.incb.org/documents/Psychotropics/conventions/convention_1971_fr.pdf

Nations Unies. Convention Unique sur les Stupéfiants de 1961 telle que modifiée par le Protocole de 1972 portant amendement de la Convention Unique sur les Stupéfiants de 1961 [Internet]. Geneva, Switzerland; 1972 [cité 1 sept 2013]. Disponible sur: http://www.incb.org/documents/Narcotic-Drugs/1961-Convention/convention_1961_fr.pdf Nawrot TS, Perez L, Künzli N, Munters E, Nemery B. Public health importance of triggers of

myocardial infarction: a comparative risk assessment. Lancet. 2011; 377: 732‑740. Nichols DE. Hallucinogens. Pharmacol. Ther. 2004; 101: 131‑181.

[No authors listed]. Adverse effects of cannabis. Prescrire Int. 2011; 20: 18‑23.

Nordmann S, Pradel V, Lapeyre-Mestre M, Frauger E, Pauly V, Thirion X, Mallaret M, Jouanjus E, Micallef J. Doctor shopping reveals geographical variations in opioid abuse. Pain Physician. 2013; 16: 89‑100.

O’Daly OG, Trick L, Scaife J, Marshall J, Ball D, Phillips ML, Williams SSC, Stephens DN, Duka T. Withdrawal-associated increases and decreases in functional neural connectivity associated with altered emotional regulation in alcoholism. Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 2012; 37: 2267‑2276.

O’Sullivan SE, Tarling EJ, Bennett AJ, Kendall DA, Randall MD. Novel time-dependent

Dans le document Identification des complications graves associées à l'usage de substances psychoactives (Page 143-197)